Education

Undergraduate School

University of California at Berkley
1987 Berkley CA

Medical School

University of Vermont
1992 Burlington VT

Residency

Rhode Island Hospital, Brown University
Providence RI

Fellowship

Tufts New England Floating Hospital for Children
Boston MA

Fellowship

Boston Children's Hospital
Boston MA

Publications

  1. The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia. Exp Cell Res. 2024 Apr 15; 437(2):114015. View Abstract
  2. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology. 2022 12; 163(6):1510-1521.e6. View Abstract
  3. Electron Signatures of Reconnection in a Global eVlasiator Simulation. Geophys Res Lett. 2022 Jul 28; 49(14):e2022GL098329. View Abstract
  4. Quasi-Parallel Shock Reformation Seen by Magnetospheric Multiscale and Ion-Kinetic Simulations. Geophys Res Lett. 2022 Jan 28; 49(2):e2021GL096335. View Abstract
  5. Vulvar Crohn's Disease: Clinical Features and Outcomes. Am J Gastroenterol. 2021 11 01; 116(11):2296-2299. View Abstract
  6. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohns Colitis 360. 2021 Jul; 3(3):otab019. View Abstract
  7. A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Inflamm Bowel Dis. 2021 04 15; 27(5):594-602. View Abstract
  8. Parasitic omental endometrioma: an unexpected iatrogenic sequalae of morcellation in disseminating de novo benign peritoneal disease. J Obstet Gynaecol. 2021 Jan; 41(1):167-168. View Abstract
  9. Perineal integrity can be guarded by polishing our intrapartum skills. Aust N Z J Obstet Gynaecol. 2020 06; 60(3):E6. View Abstract
  10. Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2021 03; 19(3):616-617. View Abstract
  11. Intravenous Bevacizumab Reduces Transfusion Requirements and Endoscopic Interventions in Patients With Gastric Antral Vascular Ectasia and Small Bowel Angioectasia. Gastroenterology. 2020 03; 158(4):1162-1163.e4. View Abstract
  12. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. J Clin Med. 2019 Aug 05; 8(8). View Abstract
  13. Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational study. Eur J Obstet Gynecol Reprod Biol. 2019 Sep; 240:62-67. View Abstract
  14. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 02 21; 25(3):580-586. View Abstract
  15. Narrow band imaging evaluation of duodenal villi in patients with and without celiac disease: A prospective study. World J Gastrointest Endosc. 2019 Feb 16; 11(2):145-154. View Abstract
  16. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019 01; 94(1):155-165. View Abstract
  17. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis. 2018 09 15; 24(10):2272-2277. View Abstract
  18. Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. J Crohns Colitis. 2018 Jul 30; 12(8):973-980. View Abstract
  19. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflamm Bowel Dis. 2018 06 08; 24(7):1582-1588. View Abstract
  20. Concurrent Sweet's syndrome and myopericarditis following mesalamine therapy. BMJ Case Rep. 2018 Mar 23; 2018. View Abstract
  21. Targeting Specific Immunologic Pathways in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):577-588. View Abstract
  22. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Gut Liver. 2017 Jul 15; 11(4):455-463. View Abstract
  23. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Autoimmunity. 2017 May; 50(3):170-181. View Abstract
  24. P616 Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease. J Crohns Colitis. 2017 Feb 01; 11(suppl_1):S394-S395. View Abstract
  25. The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). J Biol Chem. 2017 Jan 13; 292(2):706-722. View Abstract
  26. O-015 YI Alterations in the FOXP3-EZH2 Pathway Associates with Increased Susceptibility to Colitis in Both Mice and Human. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S5-6. View Abstract
  27. A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol. 2016 Feb 24; 16:20. View Abstract
  28. Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. Am J Physiol Gastrointest Liver Physiol. 2015 Dec 01; 309(11):G900-9. View Abstract
  29. Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Oncogene. 2016 05 12; 35(19):2496-505. View Abstract
  30. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015 Aug; 25(4):321-7. View Abstract
  31. New-onset paresthesias in inflammatory bowel disease. Gastroenterology. 2015 May; 148(5):906-7. View Abstract
  32. An uncommon cause of abdominal pain and fever in a patient with Crohn's disease. Gastroenterology. 2015 May; 148(5):e12-3. View Abstract
  33. A novel role for KLF14 in T regulatory cell differentiation. Cell Mol Gastroenterol Hepatol. 2015 Mar 01; 1(2):188-202.e4. View Abstract
  34. Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015 May; 60(5):1366-74. View Abstract
  35. Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-ß signaling in CD8+ T lymphocytes. Am J Physiol Cell Physiol. 2015 Mar 01; 308(5):C362-71. View Abstract
  36. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics. 2014 Dec; 15(16):2049-62. View Abstract
  37. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am. 2014 Sep; 43(3):405-24. View Abstract
  38. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am. 2014 Sep; 43(3):581-601. View Abstract
  39. Prolonged idiopathic gastric dilatation following revascularization for chronic mesenteric ischemia. Ann Gastroenterol. 2014; 27(3):273-275. View Abstract
  40. Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Inflamm Bowel Dis. 2013 Oct; 19(11):2394-9. View Abstract
  41. Chronic diarrhea after autologous stem cell transplantation for peripheral T-cell lymphoma. Gastroenterology. 2013 Aug; 145(2):e3-5. View Abstract
  42. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2013 Sep; 7(8):e286-91. View Abstract
  43. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2013 Feb 10; 165(3):163-72. View Abstract
  44. Colorectal cancer screening and surveillance in Crohn's colitis. J Crohns Colitis. 2012 Sep; 6(8):824-9. View Abstract
  45. Predicting outcomes after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2012 May; 10(5):447-9. View Abstract
  46. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011 Feb; 5(1):59-66. View Abstract
  47. Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J Crohns Colitis. 2010 Oct; 4(4):390-7. View Abstract
  48. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis. 2010 Aug; 16(8):1279-85. View Abstract
  49. A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. J Crohns Colitis. 2010 Sep; 4(3):349-50. View Abstract
  50. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010 Oct; 4(4):367-76. View Abstract
  51. CD8+ cells protect mice against reinfection with the intestinal parasite Eimeria falciformis. Microbes Infect. 2010 Mar; 12(3):218-26. View Abstract
  52. Diagnostic approach to small bowel involvement in inflammatory bowel disease: view of the endoscopist. Dig Dis. 2009; 27(4):476-81. View Abstract
  53. Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. Gastrointest Endosc. 2010 Jan; 71(1):121-7. View Abstract
  54. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 Jan; 105(1):148-54. View Abstract
  55. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009 Jun; 41(6):666-76. View Abstract
  56. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009 Dec; 15(12):1915-24. View Abstract
  57. Crohn's disease: Adalimumab improves quality of life. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):200-1. View Abstract
  58. Comparison of commercially available serologic kits for the detection of celiac disease. J Clin Gastroenterol. 2009 Mar; 43(3):225-32. View Abstract
  59. Capsule endoscopy in the evaluation and management of inflammatory bowel disease: a future perspective. Expert Rev Mol Diagn. 2009 Jan; 9(1):31-6. View Abstract
  60. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009 Jan; 41(1):25-34. View Abstract
  61. Why are cytokines targeted for biological therapy in IBD? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S121-2. View Abstract
  62. Endoscopic evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Sep; 14(9):1287-97. View Abstract
  63. Proximal small intestinal CD detected by CE. Gastrointest Endosc. 2008 Jul; 68(1):202-3; author reply 203-4. View Abstract
  64. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun; 127(3):322-9. View Abstract
  65. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008 Jun; 40(6):768-75. View Abstract
  66. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008 May; 6(5):561-8. View Abstract
  67. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis. 2008 Jun; 40(6):425-32. View Abstract
  68. LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008 Feb 09; 371(9611):483-91. View Abstract
  69. Minimally invasive closure of pediatric umbilical hernias. J Pediatr Surg. 2008 Jan; 43(1):127-30. View Abstract
  70. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008 Jan; 51(1):100-8. View Abstract
  71. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). Endoscopy. 2008 Jan; 40(1):30-5. View Abstract
  72. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007 Nov; 50(11):1747-53. View Abstract
  73. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol. 2007 Dec; 125(3):281-90. View Abstract
  74. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007 Nov; 102(11):2488-94. View Abstract
  75. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):952-8; quiz 887. View Abstract
  76. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007 May; 5(5):602-8; quiz 525. View Abstract
  77. Esophageal Crohn's disease treated successfully with adalimumab. Inflamm Bowel Dis. 2007 May; 13(5):639-40. View Abstract
  78. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis. 2007 May; 13(5):524-30. View Abstract
  79. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol. 2007 Mar 01; 178(5):3293-300. View Abstract
  80. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):191-9. View Abstract
  81. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis. 2006 Dec; 12(12):1122-30. View Abstract
  82. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007 Feb; 132(2):576-86. View Abstract
  83. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006 Aug; 101(8):1834-40. View Abstract
  84. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006 Apr; 130(4):1078-85. View Abstract
  85. Adalimumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2006 Jan; 2(1):11-5. View Abstract
  86. Wireless capsule endoscopy in the evaluation of patients with suspected or known Crohn's disease. Endoscopy. 2005 Oct; 37(10):1018-22. View Abstract
  87. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg. 2005 Oct; 71(10):821-6. View Abstract
  88. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005 Jun; 48(6):1254-62. View Abstract
  89. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005 Jun; 128(7):2020-8. View Abstract
  90. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol. 2005 Apr 15; 174(8):4985-90. View Abstract
  91. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005 Apr; 39(4):303-6. View Abstract
  92. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005 Jan; 100(1):75-9. View Abstract
  93. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis. 2004 Nov; 10(6):778-88. View Abstract
  94. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut. 2004 Sep; 53(9):1389-90. View Abstract
  95. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004 Jul; 10(4):333-8. View Abstract
  96. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 Jul; 10(4):352-6. View Abstract
  97. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol. 2004 Jun 01; 172(11):7002-7. View Abstract
  98. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):309-13. View Abstract
  99. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004 Feb; 126(2):414-24. View Abstract
  100. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004 Jan; 2(1):31-40. View Abstract
  101. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004 Jan; 4(1):83-9. View Abstract
  102. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003 Oct 01; 18(7):741-7. View Abstract
  103. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol. 2003 Jul 01; 171(1):159-65. View Abstract
  104. Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003 May-Jun; 36(5):379-81. View Abstract
  105. Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology. 2003 Feb; 124(2):583. View Abstract
  106. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002 Sep; 123(3):679-88. View Abstract
  107. Diagnosis and misdiagnosis of inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002 Jul; 12(3):433-49. View Abstract
  108. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology. 2001 Aug; 121(2):246-54. View Abstract
  109. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001 Jul; 96(7):2137-42. View Abstract
  110. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol. 2000 Nov 01; 165(9):5069-76. View Abstract
  111. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis. 2000 Nov; 6(4):303-13. View Abstract
  112. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000 Oct; 119(4):1148-57. View Abstract
  113. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98. View Abstract
  114. Serologic testing in inflammatory bowel disease: its value in indeterminate colitis. Curr Gastroenterol Rep. 1999 Dec; 1(6):482-5. View Abstract
  115. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999 Dec; 117(6):1278-87. View Abstract
  116. Recurrent bleeding from a duodenal plasmacytoma treated successfully with embolization of the gastroduodenal artery. Am J Gastroenterol. 1999 Jun; 94(6):1691-2. View Abstract
  117. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):283-96. View Abstract
  118. The role of apoptosis in normal and accelerated lung development in fetal rabbits. J Pediatr Surg. 1999 May; 34(5):863-70; discussion 870-1. View Abstract
  119. The changing presentation of pyloric stenosis. Am J Emerg Med. 1999 Jan; 17(1):67-9. View Abstract
  120. Predictive value of monitoring parameters in fetal surgery. J Pediatr Surg. 1998 Aug; 33(8):1297-301. View Abstract
  121. Temporary tracheal occlusion causes catch-up lung maturation in a fetal model of diaphragmatic hernia. J Pediatr Surg. 1998 Jul; 33(7):1030-7. View Abstract
  122. Single-port tracheoscopic surgery in the fetal lamb. J Pediatr Surg. 1998 Jun; 33(6):918-20. View Abstract
  123. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg. 1997 Jul; 87(1):106-8. View Abstract
  124. Fetal lung growth after tracheal ligation is not solely a pressure phenomenon. J Pediatr Surg. 1997 Feb; 32(2):347-51. View Abstract
  125. Patterns of pulmonary metastasis from uterine cancer. Oncology. 1996 Sep-Oct; 53(5):360-3. View Abstract
  126. Natural history of patients with pulmonary metastases from uterine cancer. Cancer. 1996 Aug 01; 78(3):441-7. View Abstract
  127. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996 Aug; 101(2):170-6. View Abstract
  128. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996 Mar; 22(3):508-12. View Abstract
  129. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med. 1996 Feb 26; 156(4):433-5. View Abstract
  130. Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Clin Infect Dis. 1996 Feb; 22(2):388-9. View Abstract
  131. Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis. 1995 Oct; 21(4):1032-4. View Abstract

Contact Konstantinos Papadakis

Print Profile